ID   NZM012
AC   CVCL_D818
SY   NZM12
DR   BioSample; SAMN07624441
DR   BioSample; SAMN14558321
DR   cancercelllines; CVCL_D818
DR   CBA; CBA-1383
DR   Cosmic; 1660300
DR   Wikidata; Q54931528
RX   CelloPub=CLPUB00227;
RX   PubMed=11216673;
RX   PubMed=20041153;
RX   PubMed=22475322;
RX   PubMed=23755070;
RX   PubMed=32567790;
CC   Doubling time: 25.9 hours (CelloPub=CLPUB00227); 40-42 hours (CBA=CBA-1383).
CC   HLA typing: A*02:01,32:01; B*44:02,44:02; C*01:02,05:01 (PubMed=32567790).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=23755070; PubMed=32567790).
CC   Sequence variation: Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790).
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: Metastatic; Small intestine; UBERON=UBERON_0002108.
ST   Source(s): CBA=CBA-1383; PubMed=32567790
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 10,11
ST   D16S539: 11,12
ST   D18S51: 12
ST   D19S433: 12,13
ST   D21S11: 28,29
ST   D2S1338: 23,25
ST   D3S1358: 15,16
ST   D5S818: 9,12
ST   D7S820: 10,12
ST   D8S1179: 11,14
ST   FGA: 20,23
ST   Penta D: 9,13
ST   Penta E: 5,16
ST   TH01: 7
ST   TPOX: 8
ST   vWA: 14,17
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   19Y
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 19-12-24; Version: 21
//
RX   CelloPub=CLPUB00227;
RA   Daukste L.;
RT   "Mathematical modelling of cancer cell population dynamics.";
RL   Thesis PhD (2012); University of Canterbury; Christchurch; New Zealand.
//
RX   PubMed=11216673; DOI=10.3727/096504001108747620;
RA   Parmar J., Marshall E.S., Charters G.A., Holdaway K.M., Shelling A.N.,
RA   Baguley B.C.;
RT   "Radiation-induced cell cycle delays and p53 status of early passage
RT   melanoma cell lines.";
RL   Oncol. Res. 12:149-155(2000).
//
RX   PubMed=20041153; DOI=10.1371/journal.pone.0008461; PMCID=PMC2794539;
RA   Jeffs A.R., Glover A.C., Slobbe L.J., Wang L., He S.-J., Hazlett J.A.,
RA   Awasthi A., Woolley A.G., Marshall E.S., Joseph W.R., Print C.G.,
RA   Baguley B.C., Eccles M.R.;
RT   "A gene expression signature of invasive potential in metastatic
RT   melanoma cells.";
RL   PLoS ONE 4:E8461-E8461(2009).
//
RX   PubMed=22475322; DOI=10.1186/1471-2407-12-141; PMCID=PMC3352269;
RA   Kim J.E., Stones C.J., Joseph W.R., Leung E.Y., Finlay G.J.,
RA   Shelling A.N., Phillips W.A., Shepherd P.R., Baguley B.C.;
RT   "Comparison of growth factor signalling pathway utilisation in
RT   cultured normal melanocytes and melanoma cell lines.";
RL   BMC Cancer 12:141.1-141.10(2012).
//
RX   PubMed=23755070; DOI=10.3389/fgene.2013.00097; PMCID=PMC3668138;
RA   Kim J.E., Leung E.Y., Baguley B.C., Finlay G.J.;
RT   "Heterogeneity of expression of epithelial-mesenchymal transition
RT   markers in melanocytes and melanoma cell lines.";
RL   Front. Genet. 4:97.1-97.8(2013).
//
RX   PubMed=32567790; DOI=10.1111/pcmr.12908; PMCID=PMC7818249;
RA   Tran K.B., Gimenez G., Tsai P., Kolekar S., Rodger E.J.,
RA   Chatterjee A., Jabed A., Shih J.-H., Joseph W.R., Marshall E.S.,
RA   Wang Q., Print C.G., Eccles M.R., Baguley B.C., Shepherd P.R.;
RT   "Genomic and signalling pathway characterization of the NZM panel of
RT   melanoma cell lines: a valuable model for studying the impact of
RT   genetic diversity in melanoma.";
RL   Pigment Cell Melanoma Res. 34:136-143(2021).
//